Morepen Laboratories Completes Phase One of Manufacturing Capacity Expansion Ahead of Schedule
Morepen Laboratories Limited has successfully completed the first phase of its manufacturing capacity expansion program, achieving this milestone ahead of the previously indicated timeline.The capacity enhancement specifically targeted the installed reactor capacity for API and CDMO. Under this phase one project, the company's reactor capacity increased from 535 KL to 614 KL.
This significant capacity increase is intended to strengthen the company’s manufacturing readiness for the ongoing scale-up of commercial CDMO supplies. Furthermore, the expansion will support both Morepen's existing API business and future customer programs.
The completed phase marks a critical milestone in Morepen's strategy to develop a larger, scalable, and globally compliant manufacturing platform. This initiative is focused on fostering long-duration customer partnerships and driving sustained growth across both its API and CDMO businesses.
MOREPENLAB Stock Price Movement
Shares of MOREPEN LABORATORIES LIMITED are edging higher to ₹115.96 as of 9:31 AM, gaining 1.95% in live trading. The stock's trading volume is currently at 328,979 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.